FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

27567911000001101: Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 12-Nov 2014. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
87497501000001113 Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
87497601000001112 Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Has NHS dm+d (dictionary of medicines and devices) additional monitoring indicator EMA (European Medicines Agency) monitoring true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Is a Umeclidinium bromide 65micrograms/dose dry powder inhaler true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Has specific active ingredient Umeclidinium bromide false Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Has dispensed dose form Conventional release powder for inhalation true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Has excipient Lactose false Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Is a Incruse Ellipta true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Has specific active ingredient Umeclidinium bromide true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Has manufactured dose form Conventional release powder for inhalation true Inferred relationship Existential restriction modifier
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Has active ingredient Substance with muscarinic receptor antagonist mechanism of action true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has AMP True Incruse Ellipta 55micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start